

RESPONSE UNDER 37 CFR 1.116  
EXPERIMENTAL PROCEDURE  
EXAMINING GROUP 1645

PATENT

Rev 05/03


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Kerstin Krieglstein  
Application No. : 09/786,435  
Filed : March 20, 2001  
Confirmation No. : 1324  
For : USE OF TGF-BETA INHIBITORS FOR TREATING  
CEREBRAL DISORDERS  
Examiner : Vanessa L. Ford  
Attorney's Docket : MBP-005XX

TC Art Unit: 1645

\*\*\*\*\*  
I hereby certify that this correspondence is being sent via facsimile to  
Examiner Vanessa L. Ford, Group Art Unit 1645, Fax No. (703) 308-4242,  
on 10-17-3.

By:

  
Charles L. Gagnebin III  
Registration No. 25,467  
Attorney for Applicant(s)

\*\*\*\*\*

AMENDMENT UNDER 37 C.F.R. §1.116

RECEIVED  
CENTRAL FAX CENTER

OCT 20 2003

Via Facsimile  
Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

OFFICIAL

Sir:

In response to the final Office Action dated June 17, 2003  
(Paper No. 10), please amend the above-identified patent  
application as follows.

WEINGARTEN, SCHURGIN,  
GAGNEBIN & DEBOVICI LLP  
TEL. (617) 542-2290  
FAX. (617) 431-0313